Literature DB >> 7066891

Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).

T H Corbett, W R Leopold, D J Dykes, B J Roberts, D P Griswold, F M Schabel.   

Abstract

A new triazine folate antagonist, 3-chloro-4-((4-(2-chloro-4-[4,6-diamino-2,2-dimethyl-s-triazin-1(2H)-yl]phenyl)butyl)) benzenesulfonyl fluoride compounded with ethanesulfonic acid (1:1) (NSC 127755), was highly active against four transplantable colon adenocarcinomas (36, 38, 10/A, 12/A) and the Dunning murine ovarian tumor M5076. Treatment schedule studies indicated that a prolonged time of exposure provided optimum antitumor activity for the compound. The combination of NSC 127755 plus 4-amino-1-[5-O-(1-oxohexadecyl)-beta-D-arabinofuranosyl]-2(1H)-pyrimidinone (palmO-ara-C, NSC 135962) was found to have therapeutic synergism against grossly evident colon adenocarcinoma 36.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7066891

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  23 in total

1.  Activity of batracylin (NSC-320846) against solid tumors of mice.

Authors:  P Mucci-LoRusso; L Polin; M C Bissery; F Valeriote; J Plowman; G D Luk; T H Corbett
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Authors:  Johanne Seguin; Céline Nicolazzi; Nathalie Mignet; Daniel Scherman; Guy G Chabot
Journal:  Tumour Biol       Date:  2012-06-07

3.  Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.

Authors:  L Polin; F Valeriote; K White; C Panchapor; S Pugh; J Knight; P LoRusso; M Hussain; E Liversidge; N Peltier; T Golakoti; G Patterson; R Moore; T H Corbett
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 4.  The marine bromotyrosine derivatives.

Authors:  Jiangnan Peng; Jing Li; Mark T Hamann
Journal:  Alkaloids Chem Biol       Date:  2005

5.  Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate.

Authors:  T H Corbett; P LoRusso; L Demchick; C Simpson; S Pugh; K White; J Kushner; L Polin; J Meyer; J Czarnecki; L Heilbrun; J P Horwitz; J L Gross; C H Behrens; B A Harrison; R J McRipley; G Trainor
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

6.  Comparative efficacy of DMP 840 against mouse and human solid tumor models.

Authors:  P LoRusso; L Demchik; M Dan; L Polin; J L Gross; T H Corbett
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

7.  In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

Authors:  B J Roberts; K L Hamelehle; J S Sebolt; W R Leopold
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Is the P388 murine tumor no longer adequate as a drug discovery model?

Authors:  T H Corbett; F A Valeriote; L H Baker
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

9.  Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.

Authors:  E Tapazoglou; L Polin; T H Corbett; M al-Sarraf
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

Review 10.  5-Fluorouracil containing combinations in murine tumor systems.

Authors:  T H Corbett; M C Bissery; P Mucci-LoRusso; L Polin
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.